Bioinformatic Evaluation of Transcriptional Regulation of WNT Pathway Genes with reference to Diabetic Nephropathy

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  McKay, Gareth J ^a   Kavanagh, David H ^a   Crean, John K ^b   Maxwell, Alexander P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID ZINC FINGER 1 PROTEIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; BINDING SITE; BIOINFORMATICS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY; BIOLOGY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC TRANSCRIPTION; GENETICS;

BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; HUMANS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; WNT SIGNALING PATHWAY;

EID: 84949956140     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/7684038     Document Type: Article

References (51)

1. J. Gilg, C. Castledine, and D. Fogarty, "Chapter 1 UK RRT incidence in 2010: national and centre-specific analyses," Nephron Clinical Practice, vol. 120, supplement 1, pp. c1-c27, 2012.
2. C. J. Hill, C. R. Cardwell, C.C. Patterson et al., "Chronic kidney disease and diabetes in the national health service: a crosssectional survey of the U.K. national diabetes audit," Diabetic Medicine, vol. 31, no. 4, pp. 448-454, 2014.
3. N. Sandholm, R. M. Salem, A. J. McKnight et al., "New susceptibility loci associated with kidney disease in type 1 diabetes," PLoS Genetics, vol. 8, no. 9, Article ID e1002921, 2012.
4. V. Harjutsalo, S. Katoh, C. Sarti, N. Tajima, and J. Tuomilehto, "Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes," Diabetes, vol. 53, no. 9, pp. 2449-2454, 2004.
5. B. I. Freedman, C. D. Langefeld, L. Lu et al., "Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans," PLoS Genetics, vol. 7, no. 6, Article ID e1002150, 2011.
6. W. He, C. Dai, Y. Li, G. Zeng, S. P. Monga, and Y. Liu, "Wnt/β- catenin signaling promotes renal interstitial fibrosis," Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 765-776, 2009.
7. C.-L. Lin, J.-Y. Wang, J.-Y. Ko, Y.-T. Huang, Y.-H. Kuo, and F.-S. Wang, "Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangialmatrix and renal dysfunction," Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 124-135, 2010.
8. C. Ho, P.-H. Lee, Y.-C. Hsu, F.-S. Wang, Y.-T. Huang, and C.-L. Lin, "Sustained Wnt/β-catenin signaling rescues high glucose induction of transforming growth factor-β1-mediated renal fibrosis," American Journal of the Medical Sciences, vol. 344, no. 5, pp. 374-382, 2012.
9. N. Faherty, H. O'Donovan, D. Kavanagh et al., "TGFβ and CCN2/CTGFmediate actin related gene expression by differential E2F1/CREB activation," BMC Genomics, vol. 14, article 525, 2013.
10. S. Steinberg, S. de Jong, O. A. Andreassen et al., "Common variants at VRK2 and TCF4 conferring risk of schizophrenia," Human Molecular Genetics, vol. 20, no. 20, Article ID ddr325, pp. 4076-4081, 2011.
11. M. T. Veeman, J. D. Axelrod, and R. T. Moon, "A second canon: functions and mechanisms of β-catenin-independent Wnt signaling," Developmental Cell, vol. 5, no. 3, pp. 367-377, 2003.
12. R. Habas and I. B. Dawid, "Dishevelled and Wnt signaling: is the nucleus the final frontier?" Journal of Biology, vol. 4, no. 1, article 2, 2005.
13. Y. Liu, "New insights into epithelial-mesenchymal transition in kidney fibrosis," Journal of the American Society of Nephrology, vol. 21, no. 2, pp. 212-222, 2010.
14. L. Ivanova, M. J. Butt, and D. G. Matsell, "Mesenchymal transition in kidney collecting duct epithelial cells," The American Journal of Physiology-Renal Physiology, vol. 294, no. 5, pp. F1238-F1248, 2008.
15. U. Ullmann, C. Gilles, M. De Rycke, H. Van de Velde, K. Sermon, and I. Liebaers, "GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions," Molecular Human Reproduction, vol. 14, no. 3, pp. 169-179, 2008.
16. M. Levine and R. Tjian, "Transcription regulation and animal diversity," Nature, vol. 424, no. 6945, pp. 147-151, 2003.
17. G. Orphanides, T. Lagrange, and D. Reinberg, "The general transcription factors of RNA polymerase II," Genes and Development, vol. 10, no. 21, pp. 2657-2683, 1996.
18. T. I. Lee and R. A. Young, "Transcription of eukaryotic proteincoding genes," Annual Review of Genetics, vol. 34, pp. 77-137, 2000.
19. J. W. Conaway, L. Florens, S. Sato et al., "The mammalian mediator complex," FEBS Letters, vol. 579, no. 4, pp. 904-908, 2005.
20. G. A. Maston, S. K. Evans, and M. R. Green, "Transcriptional regulatory elements in the human genome," Annual Review of Genomics and Human Genetics, vol. 7, pp. 29-59, 2006.
21. M. Ptashne and A. Gann, "Transcriptional activation by recruitment," Nature, vol. 386, no. 6625, pp. 569-577, 1997.
22. D.H. Kavanagh, D. A. Savage, C.C. Patterson et al., "Association analysis of canonical Wnt signalling genes in diabetic nephropathy," PLoS ONE, vol. 6, no. 8, Article ID e23904, 2011.
23. D. H. Kavanagh, D. A. Savage, C. C. Patterson et al., "Haplotype association analysis of genes within the WNT signalling pathways in diabetic nephropathy," BMC Nephrology, vol. 14, no. 1, article 126, 2013.
24. R. Elkon, C. Linhart, R. Sharan, R. Shamir, and Y. Shiloh, "Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells," Genome Research, vol. 13, no. 5, pp. 773-780, 2003.
25. W. W. Wasserman and A. Sandelin, "Applied bioinformatics for the identification of regulatory elements," Nature Reviews Genetics, vol. 5, no. 4, pp. 276-287, 2004.
26. R. C. McLeay and T. L. Bailey, "Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data," BMC Bioinformatics, vol. 11, article 165, 2010.
27. J. C. Bryne, E. Valen, M.-H. E. Tang et al., "JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update," Nucleic Acids Research, vol. 36, no. 1, pp. D102-D106, 2008.
28. I.H.de Boer, T. C. Rue, Y. N. Hall, P. J. Heagerty, N. S. Weiss, and J. Himmelfarb, "Temporal trends in the prevalence of diabetic kidney disease in the United States," The Journal of the American Medical Association, vol. 305, no. 24, pp. 2532-2539, 2011.
29. M. G. Pezzolesi, G.D. Poznik, J. C. Mychaleckyj et al., "Genomewide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes," Diabetes, vol. 58, no. 6, pp. 1403-1410, 2009.
30. J. A. Bonomo, M. Guan, M. C. Ng et al., "The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease," Human Molecular Genetics, vol. 23, no. 24, pp. 6441-6447, 2014.
31. M. Kanehisa, S. Goto, M. Furumichi, M. Tanabe, and M. Hirakawa, "KEGG for representation and analysis of molecular networks involving diseases and drugs," Nucleic Acids Research, vol. 38, no. 1, pp. D355-D360, 2009.
32. H. Schmid, A. Boucherot, Y. Yasuda et al., "Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy," Diabetes, vol. 55, no. 11, pp. 2993-3003, 2006.
33. K. I. Woroniecka, A. S. D. Park, D. Mohtat, D. B. Thomas, J. M. Pullman, and K. Susztak, "Transcriptome analysis of human diabetic kidney disease," Diabetes, vol. 60, no. 9, pp. 2354-2369, 2011.
34. C. E. Hills, G. B. Willars, and N. J. Brunskill, "Proinsulin Cpeptide antagonizes the profibrotic effects of TGF-β1 via upregulation of retinoic acid and HGF-related signaling pathways," Molecular Endocrinology, vol. 24, no. 4, pp. 822-831, 2010.
35. M. J. Ryan, G. Johnson, J. Kirk, S.M. Fuerstenberg, R. A. Zager, and B. Torok-Storb, "HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney," Kidney International, vol. 45, no. 1, pp. 48-57, 1994.
36. D. Eckert, S. Buhl, S. Weber, R. Jäger, and H. Schorle, "The AP-2 family of transcription factors," Genome Biology, vol. 6, no. 13, article 246, 2005.
37. F. Orso, D. Corà, B. Ubezio, P. Provero, M. Caselle, and D. Taverna, "Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes," BMC Genomics, vol. 11, no. 1, article 355, 2010.
38. J. Pellikainen, V. Kataja, K. Ropponen et al., "Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer," Clinical Cancer Research, vol. 8, no. 11, pp. 3487-3495, 2002.
39. W. Wang, L. Lv, K. Pan et al., "Reduced expression of transcription factor AP-2α is associated with gastric adenocarcinoma prognosis," PLoS ONE, vol. 6, no. 9, Article ID e24897, 2011.
40. K. Biadasiewicz, S. Sonderegger, P. Haslinger et al., "Transcription factor AP-2α promotes EGF-dependent invasion of human trophoblast," Endocrinology, vol. 152, no. 4, pp. 1458-1469, 2011.
41. Q. Li and R. H. Dashwood, "Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells," The Journal of Biological Chemistry, vol. 279, no. 44, pp. 45669-45675, 2004.
42. J. F. Morris, R. Hromas, and F. J. Rauscher III, "Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core," Molecular and Cellular Biology, vol. 14, no. 3, pp. 1786-1795, 1994.
43. L. Bavisotto, K. Kaushansky, N. Lin, and R. Hromas, "Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro," Journal of Experimental Medicine, vol. 174, no. 5, pp. 1097-1101, 1991.
44. Y.-H. Hsieh, T.-T. Wu, J.-H. Tsai, C.-Y. Huang, Y.-S. Hsieh, and J.-Y. Liu, "PKCα expression regulated by Elk-1 and MZF-1 in human HCC cells," Biochemical and Biophysical Research Communications, vol. 339, no. 1, pp. 217-225, 2006.
45. N. Y. Tan and L. M. Khachigian, "Sp1 phosphorylation and its regulation of gene transcription," Molecular and Cellular Biology, vol. 29, no. 10, pp. 2483-2488, 2009.
46. A. K. Ghosh, Y. Mori, E. Dowling, and J. Varga, "Trichostatin A blocks TGF-β-induced collagen gene expression in skin fibroblasts: involvement of Sp1," Biochemical and Biophysical Research Communications, vol. 354, no. 2, pp. 420-426, 2007.
47. C. Baugé, O. Cauvard, S. Leclercq, P. Galéra, and K. Boumédiene, "Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta," Arthritis Research and Therapy, vol. 13, no. 1, article R23, 2011.
48. D. Zhang, J. Ma, K. Brismar, S. Efendic, and H. F. Gu, "A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study," Journal of Diabetes and its Complications, vol. 23, no. 4, pp. 265-272, 2009.
49. S. L.-A. Samson and N. C.W. Wong, "Role of Sp1 in insulin regulation of gene expression," Journal of Molecular Endocrinology, vol. 29, no. 3, pp. 265-279, 2002.
50. J. Yang and R. A. Weinberg, "Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis," Developmental Cell, vol. 14, no. 6, pp. 818-829, 2008.
51. A. P. Sanchez and K. Sharma, "Transcription factors in the pathogenesis of diabetic nephropathy," Expert Reviews in Molecular Medicine, vol. 11, article e13, 2009.